Home > Insider Trading > Filing (0001479290-23-000081)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1479290	Revance Therapeutics Inc.	RVNC	Pharmaceutical Preparations (2834)	770551645

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1529196	J Mark Foley	C/O Revance Therapeutics, Inc. 1222 Demonbreun Street, 20Th Floor Nashville TN 37203	Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-06-30	1,000	$15.61	892,933	No	4	A	Direct
Common Stock	Disposition	2023-07-03	26,279	$24.94	866,654	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	110,913	Indirect	See footnote

Footnotes

These shares were acquired by Mr. Foley under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2023 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated March 10, 2023 by Mr. Foley.
The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.73 to $25.19. Mr. Foley undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.